Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CD44 | P16070 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22675646 | 0.88 | CYP3A4 (0.59) | ALDH1A1L3MBTL1CYP3A4TDP1TSHR | |
| SCHEMBL22434026 | 0.88 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1CYP3A4TDP1TSHR | |
| SCHEMBL3781456 | 0.86 | ALDH1A1 (0.65) | ALDH1A1L3MBTL1CYP3A4TDP1TSHR | |
| SCHEMBL11402724 | 0.84 | CD44 (0.60) | ALDH1A1L3MBTL1CYP3A4TDP1TSHR | |
| SCHEMBL7647167 | 0.84 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1CYP3A4TDP1TSHR | |
| SCHEMBL398724 | 0.83 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1CYP3A4TDP1TSHR | |
| SCHEMBL218508 | 0.83 | TRPA1 (0.52) | ALDH1A1TSHRCD44NUDT1NPC1 | |
| SCHEMBL30834716 | 0.83 | TRPA1 (0.52) | ALDH1A1TSHRCD44NUDT1NPC1 | |
| SCHEMBL3787337 | 0.82 | CD44 (0.62) | ALDH1A1L3MBTL1CYP3A4TDP1TSHR | |
| SCHEMBL7939779 | 0.82 | CYP3A4 (0.56) | ALDH1A1L3MBTL1CYP3A4TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114253039-B | High brightness, saturation and purity multi-color electrochromic structure, device and manufacturing method | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-09-20 | — | — | CN | claimed |
| CN-112835241-B | Electronic equipment based on multi-color electrochromic structure and method for hiding functional components | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-06-18 | — | — | CN | claimed |
| CN-114253039-B | High brightness, saturation and purity multi-color electrochromic structure, device and manufacturing method | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-09-20 | — | — | CN | disclosed |
| CN-112835241-B | Electronic equipment based on multi-color electrochromic structure and method for hiding functional components | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-06-18 | — | — | CN | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| CN-117279909-A | Novel liver selective polyadenylation polymerase inhibitors and methods of use thereof | 巴鲁克斯布伦博格研究所 | 2023-12-22 | — | — | CN | disclosed |
| US-11739103-B2 | Processes for preparing a pan-JAK inhibitor and related intermediate compounds | Theravance Biopharma R&D LP, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| CN-115003675-A | Novel functionalized lactams as 5-hydroxytryptamine receptor 7 modulators and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-114945575-A | Novel functionalized lactones as 5-hydroxytryptamine receptor 7 modulators and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2022-08-26 | — | — | CN | disclosed |
| US-20220112219-A1 | PROCESSES FOR PREPARING A PAN-JAK INHIBITOR AND RELATED INTERMEDIATE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2022-04-14 | — | — | US | disclosed |
| EP-3746079-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | Bayer Aktiengesellschaft (DE) | 2020-12-09 | — | — | EP | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1730114-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2005087746-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
| EP-0817629-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0817629-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5631280-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1996030014-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112219-A1 | PROCESSES FOR PREPARING A PAN-JAK INHIBITOR AND RELATED INTERMEDIATE COMPOUNDS | JAK1, JAK3, JAK2 | ALDH1A1 2732/4885L3MBTL1 2884/4885CYP3A4 825/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | ALDH1A1 3514/4885L3MBTL1 882/4885CYP3A4 4672/4885 |
| US-11739103-B2 | Processes for preparing a pan-JAK inhibitor and related intermediate compounds | JAK1, JAK3, JAK2 | ALDH1A1 2732/4885L3MBTL1 2884/4885CYP3A4 825/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | ALDH1A1 2651/4885L3MBTL1 3929/4885CYP3A4 3256/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | ALDH1A1 2221/4885L3MBTL1 3693/4885CYP3A4 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.